{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:16:20Z","timestamp":1783185380682,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["DA003910"],"award-info":[{"award-number":["DA003910"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["DA041565"],"award-info":[{"award-number":["DA041565"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["DA 007268"],"award-info":[{"award-number":["DA 007268"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005300","name":"American Chemical Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005300","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","award":["DA003910"],"award-info":[{"award-number":["DA003910"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpet.2026.104902","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:00:07Z","timestamp":1777305607000},"page":"104902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced antinociception of mixed efficacy opioid peptidomimetics through P-glycoprotein modulation"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-2211","authenticated-orcid":false,"given":"Jessica P.","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-3822","authenticated-orcid":false,"given":"Kelsey E.","family":"Kochan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-3131","authenticated-orcid":false,"given":"Deanna","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Nastase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry I.","family":"Mosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Jutkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jpet.2026.104902_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/a0013628","article-title":"Opioids and the treatment of chronic pain: controversies, current status, and future directions","volume":"16","author":"Rosenblum","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"issue":"13","key":"10.1016\/j.jpet.2026.104902_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain \u2014 misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0","article-title":"Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesics drugs and routes of administration","volume":"76","author":"Cherny","year":"1995","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jpet.2026.104902_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/11630050-000000000-00000","article-title":"The appropriate treatment of chronic pain","volume":"32","author":"Sarzi-Puttini","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1034\/j.1399-6576.2001.045007795.x","article-title":"Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review","volume":"45","author":"Walder","year":"2001","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2 Suppl","key":"10.1016\/j.jpet.2026.104902_bib6","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physicaian"},{"issue":"12","key":"10.1016\/j.jpet.2026.104902_bib7","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/cb200263q","article-title":"Development and in vitro characterization of a novel bifunctional mu-agonist\/delta-antagonist opioid tetrapeptide","volume":"6","author":"Purington","year":"2011","journal-title":"ACS Chem Biol"},{"issue":"23","key":"10.1016\/j.jpet.2026.104902_bib8","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1021\/jm9007483","article-title":"Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist\/antagonist properties","volume":"52","author":"Purington","year":"2009","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.jpet.2026.104902_bib9","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1021\/jm980724+","article-title":"The opioid mu agonist\/delta antagonist DIPP-NH2(psi) produces a potent analgesic effect, no physical dependence and less tolerance than morphine in rats","volume":"42","author":"Schiller","year":"1999","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.jpet.2026.104902_bib10","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1021\/jm00034a011","article-title":"Cyclic beta-casomorphin analgoues with mixed mu agonist\/delta antagonist properties: synthesis, pharmacological characterization and conformational aspects","volume":"37","author":"Schmidt","year":"1994","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.jpet.2026.104902_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cbdd.12014","article-title":"Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models","volume":"80","author":"Anand","year":"2012","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib12","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bmc.2014.02.015","article-title":"Endomorphin analogues with mixed mu opioid (MOP) receptor agonism\/delta opioid (DOP) receptor antagonism and lacking beta arrestin2 recruitment activity","volume":"22","author":"Cai","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"25","key":"10.1016\/j.jpet.2026.104902_bib13","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1021\/jm020336e","article-title":"Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore","volume":"45","author":"Balboni","year":"2002","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jpet.2026.104902_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/jm010449i","article-title":"Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties","volume":"45","author":"Balboni","year":"2002","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.jpet.2026.104902_bib15","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1021\/jm990165m","article-title":"Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism","volume":"42","author":"Salvadori","year":"1999","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104902_bib16","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/jm100982d","article-title":"Development of potent mu and delta opioid agonsits with high lipophilicity","volume":"54","author":"Lee","year":"2011","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.jpet.2026.104902_bib17","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/acschemneuro.5b00100","article-title":"Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy mu opioid receptor\/delta opioid receptor ligands","volume":"6","author":"Bender","year":"2015","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104902_bib18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/jm400050y","article-title":"Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy \u03bc opioid receptor (MOR) agonist\/\u03b4 opioid receptor (DOR) antagonist ligands","volume":"56","author":"Mosberg","year":"2013","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.jpet.2026.104902_bib19","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1021\/jm990039i","article-title":"Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphans","volume":"42","author":"Anathan","year":"1999","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.jpet.2026.104902_bib20","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1021\/jm030311v","article-title":"Identification of opioid ligands possessing mixed mu agonist\/delta antagonist activity among pyridomorphans derived from naloxone, oxymorphone, and hydromorphone","volume":"47","author":"Anathan","year":"2004","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jpet.2026.104902_bib21","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0022-3565(25)38254-6","article-title":"Antinociceptive profile of biphalin, a dimeric enkephalin analog","volume":"265","author":"Horan","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.jpet.2026.104902_bib22","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/cn4000428","article-title":"Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed \u03bc agonist\/\u03b4 antagonist opioid analgesic with reduced tolerance liabilities","volume":"4","author":"Healy","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"13","key":"10.1016\/j.jpet.2026.104902_bib23","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00213-016-4296-8","article-title":"The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice","volume":"233","author":"Anand","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"1-3","key":"10.1016\/j.jpet.2026.104902_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2007.02.040","article-title":"Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores","volume":"566","author":"Lenard","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"10.1016\/j.jpet.2026.104902_bib25","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1021\/acs.jmedchem.5b01270","article-title":"Further optimization and evaluation of bioavailable, mixed-efficacy mu-opioid receptor (MOR) agonists\/delta-opioid receptor (DOR) antagonists: balancing MOR and DOR affinities","volume":"58","author":"Harland","year":"2015","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104902_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br J Pain"},{"issue":"1","key":"10.1016\/j.jpet.2026.104902_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","article-title":"Delivery of therapeutic agents to the central nervous system: the problems and the possibilities","volume":"104","author":"Begley","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.jpet.2026.104902_bib28","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2174\/1381612043384844","article-title":"ABC transporters and the blood-brain barrier","volume":"10","author":"Begley","year":"2004","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00004647-199707000-00001","article-title":"Drug delivery to the brain","volume":"17","author":"Pardridge","year":"1997","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"10.1016\/j.jpet.2026.104902_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/mi.3.2.90","article-title":"Blood-brain barrier drug targeting: the future of brain drug development","volume":"3","author":"Pardridge","year":"2003","journal-title":"Mol Interv"},{"issue":"3","key":"10.1016\/j.jpet.2026.104902_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/1357-4310(96)88720-X","article-title":"Transporting therapeutics across the blood-brain barrier","volume":"2","author":"Abbott","year":"1996","journal-title":"Mol Med Today"},{"issue":"3","key":"10.1016\/j.jpet.2026.104902_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Doan","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jpet.2026.104902_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","article-title":"Differential binding properties of oripavines at cloned mu- and delta-opioid receptors","volume":"378","author":"Lee","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"2-3","key":"10.1016\/j.jpet.2026.104902_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2004.12.035","article-title":"BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism","volume":"509","author":"Husbands","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2026.104902_bib35","series-title":"Guide for the Care and Use of Laboratroy Animals","author":"Council","year":"2011"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104902_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00213-016-4432-5","article-title":"The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors","volume":"234","author":"Dripps","year":"2017","journal-title":"Psychopharmacology"},{"issue":"14","key":"10.1016\/j.jpet.2026.104902_bib46","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104902_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bcp.2003.08.027","article-title":"Variable modulation of opioid brain uptake by P-glycoprotein in mice","volume":"67","author":"Dagenais","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104902_bib39","first-page":"Pl47","article-title":"Increased brain P-glycoprotein in morphine tolerant rats","volume":"66","author":"Aquilante","year":"2000","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.jpet.2026.104902_bib40","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/jps.20893","article-title":"Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel\u2019s tissue distribution in Sprague Dawley rats","volume":"96","author":"Hassan","year":"2007","journal-title":"J Pharm Sci"},{"issue":"47","key":"10.1016\/j.jpet.2026.104902_bib41","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jpet.2026.104902_bib42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bmcl.2006.12.042","article-title":"Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine","volume":"17","author":"Mercer","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.jpet.2026.104902_bib43","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1021\/jm701457j","article-title":"Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs","volume":"51","author":"Cunningham","year":"2008","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.104902_bib44","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1016\/j.bmcl.2008.04.046","article-title":"Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs","volume":"18","author":"Mercer","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"10.1016\/j.jpet.2026.104902_bib45","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.bmcl.2014.05.033","article-title":"Opioids and efflux transporters. Part 4: Influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues","volume":"24","author":"Metcalf","year":"2014","journal-title":"Bioorg Med Chem Lett"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:31:31Z","timestamp":1783182691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022356526011018"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104902","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced antinociception of mixed efficacy opioid peptidomimetics through P-glycoprotein modulation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104902"}}